share_log

Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target

Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target

Maxim Group 将 Vistagen Therapeutics 升级为收购,宣布目标股价为30美元
Benzinga ·  2023/08/07 19:09

Maxim Group analyst Jason McCarthy upgrades Vistagen Therapeutics (NASDAQ:VTGN) from Hold to Buy and announces $30 price target.

Maxim集团分析师杰森·麦卡锡将Vistagen Therapeutics(纳斯达克股票代码:VTGN)从持有上调至买入,并宣布了30美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发